Share

FDA approves Biogen Alzheimer's drug, first new therapy for the disease in nearly two decades

The U.S. Food and Drug Administration just approved Biogen's new Alzheimer's drug Aducanumab, a historic move as it is the first new therapy for the disease in nearly two decades. The drug will be marketed under the name Aduhelm and is expected to generate billions of dollars in revenue for Biogen.
01:39
Mon, Jun 7 20214:05 PM EDT